Antipsychotics for long-term treatment – when to stop? Or better not?

A new publication in the prestigious Lancet Psychiatry seems to provide new evidence for the benefits of long-term antipsychotic maintenance treatment in schizophrenia (Hui et al., Lancet Psychiatry 2018). On closer inspection, however, the paper confuses more than it provides new insights.

Cariprazine: the next touchstone for the German AMNOG

The interesting new antipsychotic compound cariprazine was recently approved by the European Medicines Agency (EMA). Its launch in Germany will be a new touchstone for the German Act on the Reform of the Market for Medicinal Products (AMNOG).